Prognostic role of caveolin in breast cancer: A meta-analysis

Breast

Volumn 22, Issue 4, 2013, Pages 462-469

  Ma, Xuelei ^a   Liu, Lei ^a   Nie, Wen ^a   Li, Yanyan ^a   Zhang, Binglan ^a   Zhang, Jing ^a   Zhou, Rubai ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Breast cancer; Caveolin; Meta analysis; Survival

Indexed keywords

CAVEOLIN; CAVEOLIN 1; CAVEOLIN 2;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EPITHELIUM CELL; HUMAN; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STROMA;

EID: 84879784560     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.03.005     Document Type: Article

References (43)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Gluz O., Liedtke C., Gottschalk N., Pusztai L., Nitz U., Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009, 20:1913-1927.
3. Yamashiro H., Toi M. Update of evidence in chemotherapy for breast cancer. Int J Clin Oncol 2008, 13:3-7.
4. Parolini I., Sargiacomo M., Galbiati F., Rizzo G., Grignani F., Engelman J.A., et al. Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the golgi complex. JBiol Chem 1999, 274:25718-25725.
5. Hnasko R., Lisanti M.P. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 2003, 3:445-464.
6. Witkiewicz A.K., Dasgupta A., Sammons S., Er O., Potoczek M.B., Guiles F., et al. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triplenegative and basal-like breast cancers. Cancer Biol Ther 2010, 10:135-143.
7. Sotgia F., Schubert W., Pestell R.G., Lisanti M.P. Genetic ablation of caveolin-1 in mammary epithelial cells increases milk production and hyper-activates STAT5a signaling. Cancer Biol Ther 2006, 5:292-297.
8. Qian N., Ueno T. Is dysfunction of caveolin-1 a link between systemic sclerosis and breast cancer, opening a window on both etiologies. Arch Med Res 2010, 41:297-301.
9. Williams T.M., Sotgia F., Lee H., Hassan G., Di V.D., Bonuccelli G., et al. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am J Pathol 2006, 169:1784-1801.
10. Liedtke C., Kersting C., Burger H., Kiesel L., Wulfing P. Caveolin-1 expression in benign and malignant lesions of the breast. World J Surg Oncol 2007, 5:110.
11. Qian N., Ueno T., Kawaguchi-Sakita N., Kawashima M., Yoshida N., Mikami Y., et al. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancerpatients. Cancer Sci 2011, 102:1590-1596.
12. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
13. Williamson P.R., Smith C.T., Hutton J.L., Marson A.G. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002, 21:3337-3351.
14. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
15. Cornfield J. Amethod of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. JNatl Cancer Inst 1951, 11:1269-1275.
16. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
17. Begg CB. Publication bias 1994;299:25.
18. Charpin C., Secq V., Giusiano S., Carpentier S., Andrac L., Lavaut M.N., et al. Asignature predictive of disease outcome in breast carcinomas, identified byquantitative immunocytochemical assays. Int J Cancer 2009, 124:2124-2134.
19. El-Gendi S.M., Mostafa M.F., El-Gendi A.M. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res 2011.
20. Elsheikh S.E., Green A.R., Rakha E.A., Samaka R.M., Ammar A.A., Powe D., et al. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like andtriple-negative immunophenotype. Br J Cancer 2008, 99:327-334.
21. Garcia S., Dales J.P., Charafe-Jauffret E., Carpentier-Meunier S., Andrac-Meyer L., Jacquemier J., et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 2007, 38:830-841.
22. Joshi B., Strugnell S.S., Goetz J.G., Kojic L.D., Cox M.E., Griffith O.L., et al. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res 2008, 68:8210-8220.
23. Koo J.S., Park S., Kim S.I., Lee S., Park B.W. The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer. Tumour Biol 2011, 32:787-799.
24. Mercier I., Bryant K.G., Sotgia F., Bonuccelli G., Witkiewicz A.K., Dasgupta A., et al. Using Caveolin-1 epithelial immunostaining patterns to stratify human breastcancer patients and predict the Caveolin-1 (P132L) mutation. Cell Cycle 2009, 8:1396-1401.
25. Savage K., Lambros M.B., Robertson D., Jones R.L., Jones C., Mackay A., et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007, 13:90-101.
26. Savage K., Leung S., Todd S.K., Brown L.A., Jones R.L., Robertson D., et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat 2008, 110:245-256.
27. Sloan E.K., Ciocca D.R., Pouliot N., Natoli A., Restall C., Henderson M.A., et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 2009, 174:2035-2043.
28. Witkiewicz A.K., Dasgupta A., Nguyen K.H., Liu C., Kovatich A.J., Schwartz G.F., et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breastcancer. Cancer Biol Ther 2009, 8:1071-1079.
29. Witkiewicz A.K., Dasgupta A., Sotgia F., Mercier I., Pestell R.G., Sabel M., et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009, 174:2023-2034.
30. Park S.S., Kim J.E., Kim Y.A., Kim Y.C., Kim S.W. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology 2005, 47:625-630.
31. Pinilla S.M., Honrado E., Hardisson D., Benitez J., Palacios J. Caveolin-1 expression is associated with a basal-like phenotype in sporadic andhereditary breast cancer. Breast Cancer Res Treat 2006, 99:85-90.
32. Sagara Y., Mimori K., Yoshinaga K., Tanaka F., Nishida K., Ohno S., et al. Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression inhuman breast cancer. Br J Cancer 2004, 91:959-965.
33. Yang G., Truong L.D., Timme T.L., Ren C., Wheeler T.M., Park S.H., et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998, 4:1873-1880.
34. Li T., Sotgia F., Vuolo M.A., Li M., Yang W.C., Pestell R.G., et al. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol 2006, 168:1998-2013.
35. Liu L.C., Su C.H., Wang H.C., Tsai C.W., Chang W.S., Ho C.Y., et al. Significant association of caveolin-1 (CAV1) genotypes with breast cancer in Taiwan. Anticancer Res 2011, 31:3511-3515.
36. Perrone G., Altomare V., Zagami M., Morini S., Petitti T., Battista C., et al. Caveolin-1 expression in human breast lobular cancer progression. Mod Pathol 2009, 22:71-78.
37. Witkiewicz A.K., Casimiro M.C., Dasgupta A., Mercier I., Wang C., Bonuccelli G., et al. Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy. Cell Cycle 2009, 8:1654-1658.
38. Hayes D.F., Isaacs C., Stearns V. Prognostic factors in breast cancer: current andnew predictors of metastasis. JMammary Gland Biol Neoplasia 2001, 6:375-392.
39. Sotgia F., Martinez-Outschoorn U.E., Howell A., Pestell R.G., Pavlides S., Lisanti M.P. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012, 7:423-467.
40. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
41. Mercier I., Casimiro M.C., Wang C., Rosenberg A.L., Quong J., Minkeu A., et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther 2008, 7:1212-1225.
42. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
43. Xie Z., Zeng X., Waldman T., Glazer R.I. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1. Cancer Res 2003, 63:5370-5375.